BioNTech to Initiate 15 Phase 3 Trials in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy BMY?
BioNTech (BNTX) will continue to execute its strategy in 2026 towards becoming a multi-product oncology company. Its diversified oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech is developing several assets with pan-tumor potential, including novel-novel combination approaches, with the aim of addressing the full continuum from early- to late-stage disease across selected tumor types. Late-Stage Acceleration: BioNTech is focused on advancing its late-stage oncology pipeline towards potential launches. Within the past two years, the company has more than doubled the number of Phase 2 and 3 oncology trials across key modalities with now more than 25 Phase 2 or 3 trials ongoing. In 2026, BioNTech plans to initiate six additional Phase 3 clinical trials, bringing the total number of anticipated Phase 3 clinical trials to 15, and expects seven late-stage data readouts. The clinical trials and resulting data will inform regulatory and launch plans. Combination Therapy Momentum: BioNTech has more than ten novel-novel combination clinical trials in its pipeline with multiple data updates expected in 2026. These trials explore pumitamig, which is being partnered with Bristol Myers Squibb (BMY), in combination with other investigational immunomodulators, ADCs, and mRNA cancer immunotherapies and will inform the dose selection and explore anti-tumor activity in multiple tumors for later-stage development. From Modalities to Disease Area: With the maturation of the oncology pipeline, BioNTech will focus on specific disease areas across major cancer types, including lung, breast, gynecologic, gastrointestinal, and genitourinary cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 62.330
Low
37.00
Averages
55.86
High
68.00
Current: 62.330
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Healthcare Stocks: Bristol Myers Squibb and Medtronic
- Market Performance of Bristol Myers Squibb: Bristol Myers Squibb boasts a robust portfolio across multiple therapeutic areas, with ten products generating over $1 billion each last year; despite facing patent expirations, the company is poised to maintain growth through new therapies, ensuring stable revenue and earnings moving forward.
- New Product Growth Drivers: The introduction of a new subcutaneous formulation of Opdivo will enhance Bristol Myers Squibb's market competitiveness, helping to sustain strong sales even after Eliquis loses patent protection, with expectations for significant revenue increases in the future.
- Innovative Products from Medtronic: Medtronic leads in the medical device sector, recently gaining clearance for the Hugo system, a robotic-assisted surgery device with significant market potential in urology, expected to drive long-term growth, especially in underpenetrated markets.
- Stable Dividend Policy: Medtronic has increased its dividends for 48 consecutive years, demonstrating resilience across various market conditions; combined with plans to spin off its diabetes care unit, this is expected to further enhance profit margins, making it an ideal choice for long-term investors.
See More
Bristol Myers Squibb and Medtronic's Dividend Growth Prospects
- Bristol Myers Squibb's Growth Strategy: Despite facing patent cliffs, Bristol Myers Squibb maintains steady revenue growth, with ten products generating over $1 billion each last year, showcasing its robust product portfolio and market adaptability.
- New Product Initiatives: The company's new subcutaneous formulation of Opdivo simplifies the administration process, expected to extend its competitiveness in the oncology market, particularly after Eliquis loses patent protection, with new therapies anticipated to significantly boost revenues.
- Medtronic's Innovation Edge: Medtronic's leadership in the medical device sector is bolstered by breakthroughs in pulsed field ablation technology, with the recent launch of the Hugo robotic surgery system poised to become a long-term growth driver, especially in underpenetrated markets.
- Consistent Dividend Growth: Medtronic has increased its dividends for 48 consecutive years, demonstrating resilience across various market conditions, making it an attractive choice for long-term income-focused investors.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
Strong Healthcare Stocks: Bristol Myers Squibb and Medtronic
- Market Performance of Bristol Myers Squibb: Bristol Myers Squibb boasts a robust portfolio across multiple therapeutic areas, with ten products generating over $1 billion each last year; despite facing patent expirations, the company is poised to maintain growth through new therapies, ensuring stable revenue and earnings moving forward.
- New Product Growth Drivers: The introduction of a new subcutaneous formulation of Opdivo will enhance Bristol Myers Squibb's market competitiveness, helping to sustain strong sales even after Eliquis loses patent protection, with expectations for significant revenue increases in the future.
- Innovative Products from Medtronic: Medtronic leads in the medical device sector, recently gaining clearance for the Hugo system, a robotic-assisted surgery device with significant market potential in urology, expected to drive long-term growth, especially in underpenetrated markets.
- Stable Dividend Policy: Medtronic has increased its dividends for 48 consecutive years, demonstrating resilience across various market conditions; combined with plans to spin off its diabetes care unit, this is expected to further enhance profit margins, making it an ideal choice for long-term investors.
See More
Bristol Myers Squibb and Medtronic's Dividend Growth Prospects
- Bristol Myers Squibb's Growth Strategy: Despite facing patent cliffs, Bristol Myers Squibb maintains steady revenue growth, with ten products generating over $1 billion each last year, showcasing its robust product portfolio and market adaptability.
- New Product Initiatives: The company's new subcutaneous formulation of Opdivo simplifies the administration process, expected to extend its competitiveness in the oncology market, particularly after Eliquis loses patent protection, with new therapies anticipated to significantly boost revenues.
- Medtronic's Innovation Edge: Medtronic's leadership in the medical device sector is bolstered by breakthroughs in pulsed field ablation technology, with the recent launch of the Hugo robotic surgery system poised to become a long-term growth driver, especially in underpenetrated markets.
- Consistent Dividend Growth: Medtronic has increased its dividends for 48 consecutive years, demonstrating resilience across various market conditions, making it an attractive choice for long-term income-focused investors.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
